Henry Schein (HSIC) 10-Q 5 Nov 13 2013 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 28, 2013	Oct. 25, 2013
Document and Entity Information [Abstract]	'	'
Document Type	'10-Q	'
Document Period End Date	28-Sep-13	'
Amendment Flag	'false	'
Document Fiscal Period Focus	'Q3	'
Document Fiscal Year Focus	'2013	'
Current Fiscal Year End Date	'--12-28	'
Entity Central Index Key	'0001000228	'
Entity Current Reporting Status	'Yes	'
Entity Filer Category	'Large Accelerated Filer	'
Entity Registrant Name	'HENRY SCHEIN INC	'
Entity Voluntary Filers	'No	'
Entity Well-known Seasoned Issuer	'Yes	'
Entity Common Stock, Shares Outstanding	'	85,854,069

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Sep. 28, 2013	Dec. 29, 2012
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$69,915	$122,080
Accounts receivable, net of reserves of $76,007 and $75,240	1,103,272	1,015,194
Inventories, net	1,123,107	1,203,507
Deferred income taxes	66,766	64,049
Prepaid expenses and other	272,360	299,547
Total current assets	2,635,420	2,704,377
Property and equipment, net	265,273	273,458
Goodwill	1,634,480	1,601,046
Other intangibles, net	431,504	462,182
Investments and other	311,412	292,934
Total assets	5,278,089	5,333,997
Current liabilities:	'	'
Accounts payable	723,905	787,658
Bank credit lines	15,751	27,166
Current maturities of long-term debt	80,588	17,992
Accrued expenses:	'	'
Payroll and related	181,444	207,381
Taxes	156,945	132,774
Other	287,812	299,738
Total current liabilities	1,446,445	1,472,709
Long-term debt	311,458	488,121
Deferred income taxes	205,263	196,814
Other liabilities	128,937	125,314
Total liabilities	2,092,103	2,282,958
Redeemable noncontrolling interests	475,021	435,175
Commitments and contingencies	'	'
Stockholders' equity:	'	'
Preferred stock, $.01 par value, 1,000,000 shares authorized, none outstanding	0	0
Common stock, $.01 par value, 240,000,000 shares authorized, 86,029,175 outstanding on September 28, 2013 and 87,850,671 outstanding on December 29, 2012	860	879
Additional paid-in capital	328,657	375,946
Retained earnings	2,328,174	2,183,905
Accumulated other comprehensive income	51,151	52,855
Total Henry Schein, Inc. stockholders' equity	2,708,842	2,613,585
Noncontrolling interests	2,123	2,279
Total stockholders' equity	2,710,965	2,615,864
Total liabilities, redeemable noncontrolling interests and stockholders' equity	$5,278,089	$5,333,997

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Sep. 28, 2013	Dec. 29, 2012
In Thousands, except Share data, unless otherwise specified
Current assets:	'	'
Accounts receivable, reserves	$76,007	$75,240
Stockholders' equity:	'	'
Preferred stock, par value (in dollars per share)	$0.01	$0.01
Preferred stock, shares authorized (in shares)	1,000,000	1,000,000
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$0.01	$0.01
Common stock, shares authorized (in shares)	240,000,000	240,000,000
Common stock, shares outstanding (in shares)	86,029,175	87,850,671

CONSOLIDATED_STATEMENTS_OF_INC

CONSOLIDATED STATEMENTS OF INCOME (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 28, 2013	Sep. 29, 2012	Sep. 28, 2013	Sep. 29, 2012
Income Statement [Abstract]	'	'	'	'
Net sales	$2,348,956	$2,231,058	$7,034,277	$6,531,529
Cost of sales	1,709,309	1,622,014	5,077,783	4,687,511
Gross profit	639,647	609,044	1,956,494	1,844,018
Operating expenses:	'	'	'	'
Selling, general and administrative	479,170	459,422	1,466,323	1,391,207
Restructuring costs	0	0	0	15,192
Operating income	160,477	149,622	490,171	437,619
Other income (expense):	'	'	'	'
Interest income	3,236	3,283	9,744	10,222
Interest expense	-5,051	-7,308	-22,668	-22,659
Other, net	1,263	988	859	2,343
Income before taxes and equity in earnings of affiliates	159,925	146,585	478,106	427,525
Income taxes	-34,660	-44,709	-135,287	-133,750
Equity in earnings of affiliates	3,642	3,434	6,209	7,898
Loss on sale of equity investment	-12,535	0	-12,535	0
Net income	116,372	105,310	336,493	301,673
Less: Net income attributable to noncontrolling interests	-8,994	-8,539	-29,207	-26,064
Net income attributable to Henry Schein, Inc.	$107,378	$96,771	$307,286	$275,609
Earnings per share attributable to Henry Schein, Inc.:	'	'	'	'
Basic (in dollars per share)	$1.25	$1.11	$3.56	$3.14
Diluted (in dollars per share)	$1.23	$1.08	$3.49	$3.06
Weighted-average common shares outstanding:	'	'	'	'
Basic (in shares)	85,646	87,465	86,208	87,802
Diluted (in shares)	87,404	89,647	87,967	90,075

CONSOLIDATED_STATEMENTS_OF_COM

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 28, 2013	Sep. 29, 2012	Sep. 28, 2013	Sep. 29, 2012
Statement of Income and Comprehensive Income [Abstract]	'	'	'	'
Net income	$116,372	$105,310	$336,493	$301,673
Other comprehensive income (loss), net of tax:	'	'	'	'
Foreign currency translation gain (loss)	53,820	22,606	-1,882	12,263
Unrealized gain (loss) from foreign currency hedging activities	-1,172	520	-538	413
Unrealized investment gain (loss)	-10	120	-93	208
Pension adjustment gain (loss)	-517	-8	490	38
Other comprehensive income (loss), net of tax	52,121	23,238	-2,023	12,922
Comprehensive income	168,493	128,548	334,470	314,595
Comprehensive income attributable to noncontrolling interests:	'	'	'	'
Net income	-8,994	-8,539	-29,207	-26,064
Foreign currency translation loss (gain)	-2,235	-643	319	-31
Comprehensive income attributable to noncontrolling interests	-11,229	-9,182	-28,888	-26,095
Comprehensive income attributable to Henry Schein, Inc.	$157,264	$119,366	$305,582	$288,500

CONSOLIDATED_STATEMENTS_OF_CHA

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (USD $)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Income [Member]	Noncontrolling Interests [Member]
In Thousands, except Share data
Beginning Balance at Dec. 29, 2012	$2,615,864	$879	$375,946	$2,183,905	$52,855	$2,279
Beginning Balance, shares (in shares) at Dec. 29, 2012	'	87,850,671	'	'	'	'
Net income (excluding amounts attributable to Redeemable noncontrolling interests)	307,621	0	0	307,286	0	335
Foreign currency translation gain (loss) (excluding amounts attributable to Redeemable noncontrolling interests)	-1,563	0	0	0	-1,563	0
Unrealized gain (loss) from foreign currency hedging activities, net of tax impact	-538	0	0	0	-538	0
Unrealized investment gain (loss), net of tax impact	-93	0	0	0	-93	0
Pension adjustment gain (loss), net of tax impact	490	0	0	0	490	0
Dividends paid	-285	0	0	0	0	-285
Initial noncontrolling interests and adjustments related to business acquisitions	-289	0	-83	0	0	-206
Change in fair value of redeemable securities	-24,455	0	-24,455	0	0	0
Repurchase and retirement of common stock - Value	-226,478	-24	-63,437	-163,017	0	0
Repurchase and retirement of common stock - Shares	'	-2,408,585	'	'	'	'
Stock issued upon exercise of stock options, including tax benefit - Value	38,902	4	38,898	0	0	0
Stock issued upon exercise of stock options, including tax benefit - Shares	'	473,347	'	'	'	'
Stock-based compensation expense - Value	24,695	3	24,692	0	0	0
Stock-based compensation expense - Shares	'	362,474	'	'	'	'
Shares withheld for payroll taxes - Value	-22,496	-2	-22,494	0	0	0
Shares withheld for payroll taxes - Shares	'	-248,732	'	'	'	'
Liability for cash settlement stock-based compensation awards	-410	0	-410	0	0	0
Ending Balance at Sep. 28, 2013	$2,710,965	$860	$328,657	$2,328,174	$51,151	$2,123
Ending Balance, shares (in shares) at Sep. 28, 2013	'	86,029,175	'	'	'	'

CONSOLIDATED_STATEMENTS_OF_CHA1

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Parenthetical) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 28, 2013
Statement of Stockholders' Equity [Abstract]	'
Net income attributable to Redeemable noncontrolling interests	$28,872
Foreign currency translation gain (loss) attributable to Redeemable noncontrolling interests	-319
Unrealized gain (loss) from foreign currency hedging activities, tax benefit (tax)	156
Unrealized investment gain (loss), tax benefit (tax)	62
Pension adjustment gain (loss), tax benefit (tax)	-77
Stock issued upon exercise of stock options, tax benefit	$16,266

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 28, 2013	Sep. 29, 2012
Cash flows from operating activities:	'	'
Net income	$336,493	$301,673
Adjustments to reconcile net income to net cash provided by operating activities:	'	'
Depreciation and amortization	96,081	91,989
Accelerated amortization of deferred financing costs	6,203	0
Loss on sale of equity investment	12,535	0
Stock-based compensation expense	24,695	31,867
Provision for losses on trade and other accounts receivable	3,477	3,338
Provision for (benefit from) deferred income taxes	-12,799	-8,478
Equity in earnings of affiliates	-6,209	-7,898
Distributions from equity affiliates	9,286	9,297
Other	14,156	10,488
Changes in operating assets and liabilities, net of acquisitions:	'	'
Accounts receivable	-93,451	-105,961
Inventories	76,877	-85,027
Other current assets	11,123	-26,788
Accounts payable and accrued expenses	-88,920	-6,062
Net cash provided by operating activities	389,547	208,438
Cash flows from investing activities:	'	'
Purchases of fixed assets	-38,733	-32,934
Payments for equity investments and business acquisitions, net of cash acquired	-34,514	-206,261
Payments related to sale of equity investment	-13,364	0
Proceeds from sales of available-for-sale securities	0	6,025
Other	-7,147	-4,130
Net cash used in investing activities	-93,758	-237,300
Cash flows from financing activities:	'	'
Proceeds from (repayments of) bank borrowings	-11,550	98,061
Proceeds from issuance of long-term debt	678,781	105,132
Debt issuance costs	-1,327	-1,404
Principal payments for long-term debt	-793,863	-38,217
Proceeds from issuance of stock upon exercise of stock options	22,636	43,773
Payments for repurchases of common stock	-226,478	-215,689
Excess tax benefits related to stock-based compensation	6,496	10,643
Distributions to noncontrolling shareholders	-18,049	-11,581
Acquisitions of noncontrolling interests in subsidiaries	-5,886	-20,013
Net cash used in financing activities	-349,240	-29,295
Net change in cash and cash equivalents	-53,451	-58,157
Effect of exchange rate changes on cash and cash equivalents	1,286	209
Cash and cash equivalents, beginning of period	122,080	147,284
Cash and cash equivalents, end of period	$69,915	$89,336

Basis_of_Presentation

Basis of Presentation	9 Months Ended
	Sep. 28, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Basis of Presentation	'
	Note 1 – Basis of Presentation
	Our consolidated financial statements include our accounts, as well as those of our wholly-owned and majority-owned subsidiaries. Certain prior period amounts have been reclassified to conform to the current period presentation.
	Our accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnote disclosures required by U.S. GAAP for complete financial statements.
	The consolidated financial statements reflect all adjustments considered necessary for a fair presentation of the consolidated results of operations and financial position for the interim periods presented. All such adjustments are of a normal recurring nature. These unaudited interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes to the consolidated financial statements contained in our Annual Report on Form 10-K for the year ended December 29, 2012.
	The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent assets and liabilities, at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The results of operations for the nine months ended September 28, 2013 are not necessarily indicative of the results to be expected for any other interim period or for the year ending December 28, 2013.

Segment_Data

Segment Data	9 Months Ended
	Sep. 28, 2013
Segment Reporting [Abstract]	'
Segment Data	'
	Note 2 – Segment Data
	We conduct our business through two reportable segments: health care distribution and technology and value-added services. These segments offer different products and services to the same customer base. The health care distribution reportable segment aggregates our global dental, animal health and medical operating segments. This segment consists of consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.
	Our global dental group serves office-based dental practitioners, schools and other institutions. Our global animal health group serves animal health practices and clinics. Our global medical group serves office-based medical practitioners, ambulatory surgery centers, other alternate-care settings and other institutions. Our global dental, animal health and medical groups serve practitioners in 25 countries worldwide.
	Our global technology and value-added services group provides software, technology and other value-added services to health care practitioners. Our technology group offerings include practice management software systems for dental and medical practitioners and animal health clinics. Our value-added practice solutions include financial services on a non-recourse basis, e-services and continuing education services for practitioners.
	The following tables present information about our reportable and operating segments:
					Three Months Ended				Nine Months Ended
					September 28,		September 29,		September 28,		September 29,
					2013		2012		2013		2012
	Net Sales:
		Health care distribution (1):
			Dental		$	1,183,201	$	1,119,430	$	3,633,577	$	3,461,015
			Animal health			642,289		598,124		1,947,728		1,709,972
			Medical			444,533		442,538		1,221,282		1,158,486
				Total health care distribution		2,270,023		2,160,092		6,802,587		6,329,473
		Technology and value-added services (2)				78,933		70,966		231,690		202,056
			Total		$	2,348,956	$	2,231,058	$	7,034,277	$	6,531,529
	-1	Consists of consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and
		generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.
	-2	Consists of practice management software and other value-added products, which are distributed primarily to health care providers, and
		financial and other services, including e-services and continuing education services for practitioners.
					Three Months Ended				Nine Months Ended
					September 28,		September 29,		September 28,		September 29,
					2013		2012		2013		2012
	Operating Income:
		Health care distribution			$	139,949	$	129,932	$	429,091	$	383,200
		Technology and value-added services				20,528		19,690		61,080		54,419
			Total		$	160,477	$	149,622	$	490,171	$	437,619

Debt

Debt	9 Months Ended
	Sep. 28, 2013
Debt Disclosure [Abstract]	'
Debt	'
	Note 3 – Debt
	Credit Facilities
	On September 12, 2012, we entered into a new $500 million revolving credit agreement (the “Credit Agreement”) with a $200 million expansion feature, which expires on September 12, 2017. This credit facility replaced our then existing $400 million revolving credit facility with a $100 million expansion feature, which would have expired on September 5, 2013. There were no borrowings outstanding under this revolving credit facility as of September 28, 2013. The interest rate is based on USD LIBOR plus a spread based on our leverage ratio at the end of each financial reporting quarter. The Credit Agreement provides, among other things, that we are required to maintain certain interest coverage and maximum leverage ratios, and contains customary representations, warranties and affirmative covenants. The Credit Agreement also contains customary negative covenants, subject to negotiated exceptions on liens, indebtedness, significant corporate changes (including mergers), dispositions and certain restrictive agreements. As of September 28, 2013, there were $10.1 million of letters of credit provided to third parties under the credit facility.
	As of September 28, 2013, we had various other short-term bank credit lines available, of which $15.8 million was outstanding. At September 28, 2013, borrowings under all of our credit lines had a weighted average interest rate of 4.26%.
	Term Loan Note
	On July 3, 2013, we entered into a $100 million term loan, of which $75.0 million was outstanding as of September 28, 2013. The interest rate on this note is LIBOR plus 75 basis points. The note was repaid in the fourth quarter of 2013.
	Private Placement Facilities
	On August 10, 2010, we entered into $400 million private placement facilities with two insurance companies. On April 30, 2012, we increased our available credit facilities by $375 million by entering into a new agreement with one insurance company and amending our existing agreements with two insurance companies. These facilities are available on an uncommitted basis at fixed rate economic terms to be agreed upon at the time of issuance, from time to time during a three year issuance period, through April 26, 2015. The facilities allow us to issue senior promissory notes to the lenders at a fixed rate based on an agreed upon spread over applicable treasury notes at the time of issuance. The term of each possible issuance will be selected by us and can range from five to 15 years (with an average life no longer than 12 years). The proceeds of any issuances under the facilities will be used for general corporate purposes, including working capital and capital expenditures, to refinance existing indebtedness and/or to fund potential acquisitions. The agreements provide, among other things, that we maintain certain maximum leverage ratios, and contain restrictions relating to subsidiary indebtedness, liens, affiliate transactions, disposal of assets and certain changes in ownership. These facilities contain make-whole provisions in the event that we pay off the facilities prior to the applicable due dates.
	The components of our private placement facility borrowings as of September 28, 2013 are presented in the following table:
		Amount of
		Borrowing		Borrowing
	Date of Borrowing	Outstanding		Rate		Due Date
	2-Sep-10	$	100,000	3.79	%	2-Sep-20
	20-Jan-12		50,000	3.45		20-Jan-24
	January 20, 2012 (1)		50,000	3.09		20-Jan-22
	24-Dec-12		50,000	3		24-Dec-24
		$	250,000
	(1) Annual repayments of approximately $7.1 million for this borrowing will commence on January 20, 2016.
	Henry Schein Animal Health
	During the first quarter of 2013, we repaid the then outstanding debt related to the Henry Schein Animal Health (“HSAH”), formerly Butler Schein Animal Health, transaction using our existing Credit Agreement. As part of this transaction, we recorded a one-time interest expense charge of $6.2 million related to the accelerated amortization of deferred financing costs.
	U.S. Trade Accounts Receivable Securitization
	On April 17, 2013, we entered into a facility agreement of up to $300 million with a bank, as agent, based on the securitization of our U.S. trade accounts receivable. The new facility allowed us to replace public debt (approximately $220 million) at a higher interest rate at HSAH during February 2013 and will provide funding for working capital and general corporate purposes. The financing is structured as an asset-backed securitization program with pricing committed for up to three years. The borrowings outstanding under this securitization facility were $20.0 million as of September 28, 2013. The interest rate on borrowings under this facility is based on the average asset-backed commercial paper rate plus 75 basis points.
	We are required to pay a commitment fee of 30 basis points on the daily balance of the unused portion of the facility if usage is greater than or equal to 50% of the facility limit or a commitment fee of 35 basis points on the daily balance of the unused portion of the facility if usage is less than 50% of the facility limit.
	Borrowings under this facility will initially be presented as a component of Long-term debt within our consolidated balance sheet.

Redeemable_Noncontrolling_Inte

Redeemable Noncontrolling Interests	9 Months Ended
	Sep. 28, 2013
Temporary Equity Disclosure [Abstract]	'
Redeemable Noncontrolling Interests	'
	Note 4 – Redeemable Noncontrolling Interests
	Some minority shareholders in certain of our subsidiaries have the right, at certain times, to require us to acquire their ownership interest in those entities at fair value. Accounting Standards Codification (“ASC”) Topic 480-10 is applicable for noncontrolling interests where we are or may be required to purchase all or a portion of the outstanding interest in a consolidated subsidiary from the noncontrolling interest holder under the terms of a put option contained in contractual agreements. The components of the change in the Redeemable noncontrolling interests for the nine months ended September 28, 2013 and the year ended December 29, 2012 are presented in the following table:
			September 28,		December 29,
			2013		2012
	Balance, beginning of period		$	435,175	$	402,050
	Decrease in redeemable noncontrolling interests due to
		redemptions		-5,124		-23,637
	Increase in redeemable noncontrolling interests due to business
		acquisitions		9,676		30,935
	Net income attributable to redeemable noncontrolling interests			28,872		34,803
	Dividends declared			-17,714		-21,013
	Effect of foreign currency translation gain (loss) attributable to
		redeemable noncontrolling interests		-319		904
	Change in fair value of redeemable securities			24,455		53,769
	Other adjustment to redeemable noncontrolling interests			-		-42,636
	Balance, end of period		$	475,021	$	435,175
	Changes in the estimated redemption amounts of the noncontrolling interests subject to put options are adjusted at each reporting period with a corresponding adjustment to Additional paid-in capital. Future reductions in the carrying amounts are subject to a “floor” amount that is equal to the fair value of the redeemable noncontrolling interests at the time they were originally recorded. The recorded value of the redeemable noncontrolling interests cannot go below the floor level. These adjustments do not impact the calculation of earnings per share.

Comprehensive_Income

Comprehensive Income	9 Months Ended
	Sep. 28, 2013
Comprehensive Income [Abstract]	'
Comprehensive Income	'
	Note 5 – Comprehensive Income
	Comprehensive income includes certain gains and losses that, under U.S. GAAP, are excluded from net income as such amounts are recorded directly as an adjustment to stockholders' equity. Our comprehensive income is primarily comprised of net income, foreign currency translation gain (loss), unrealized gain (loss) on foreign currency hedging activities, unrealized investment gain (loss) and pension adjustment gain (loss).
	The following table summarizes our Accumulated other comprehensive income, net of applicable taxes as of:
					September 28,			December 29,
					2013			2012
	Attributable to Redeemable noncontrolling interests:
			Foreign currency translation adjustment		$	-1,168		$	-849
	Attributable to Henry Schein, Inc.:
		Foreign currency translation gain			$	70,597		$	72,160
		Unrealized gain from foreign currency hedging activities				649			1,187
		Unrealized investment loss				-508			-415
		Pension adjustment loss				-19,587			-20,077
			Accumulated other comprehensive income		$	51,151		$	52,855
	Total Accumulated other comprehensive income				$	49,983		$	52,006
	The following table summarizes the components of comprehensive income, net of applicable taxes as follows:
			Three Months Ended						Nine Months Ended
			September 28,			September 29,			September 28,			September 29,
			2013			2012			2013			2012
	Net income		$	116,372		$	105,310		$	336,493		$	301,673
	Foreign currency translation gain (loss)			53,820			22,606			-1,882			12,263
	Tax effect			-			-			-			-
	Foreign currency translation gain (loss)			53,820			22,606			-1,882			12,263
	Unrealized gain (loss) from foreign currency hedging
	activities			-1,550			608			-694			518
	Tax effect			378			-88			156			-105
	Unrealized gain (loss) from foreign currency hedging
	activities			-1,172			520			-538			413
	Unrealized investment gain (loss)			-17			197			-155			380
	Tax effect			7			-77			62			-172
	Unrealized investment gain (loss)			-10			120			-93			208
	Pension adjustment gain (loss)			-696			-91			567			241
	Tax effect			179			83			-77			-203
	Pension adjustment gain (loss)			-517			-8			490			38
	Comprehensive income		$	168,493		$	128,548		$	334,470		$	314,595
	The following table summarizes our total comprehensive income, net of applicable taxes as follows:
				Three Months Ended						Nine Months Ended
				September 28,			September 29,			September 28,			September 29,
				2013			2012			2013			2012
	Comprehensive income attributable to
		Henry Schein, Inc.		$	157,264		$	119,366		$	305,582		$	288,500
	Comprehensive income attributable to
		noncontrolling interests			146			109			335			323
	Comprehensive income attributable to
		Redeemable noncontrolling interests			11,083			9,073			28,553			25,772
	Comprehensive income			$	168,493		$	128,548		$	334,470		$	314,595

Fair_Value_Measurements

Fair Value Measurements	9 Months Ended
	Sep. 28, 2013
Fair Value Disclosures [Abstract]	'
Fair Value Measurements	'
	Note 6 – Fair Value Measurements
	ASC Topic 820 “Fair Value Measurements and Disclosures” (“ASC Topic 820”) provides a framework for measuring fair value in generally accepted accounting principles.
	ASC Topic 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC Topic 820 establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity's own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs).
	The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy under ASC Topic 820 are described as follows:
	• Level 1— Unadjusted quoted prices in active markets for identical assets or liabilities that are accessible at the measurement date.
	• Level 2— Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability; and inputs that are derived principally from or corroborated by observable market data by correlation or other means.
	• Level 3— Inputs that are unobservable for the asset or liability.
	The following section describes the valuation methodologies that we used to measure different financial instruments at fair value.
	Investments and notes receivable
	There are no quoted market prices available for investments in unconsolidated affiliates and notes receivable; however, we believe the carrying amounts are a reasonable estimate of fair value.
	Debt
	The fair value of our debt as of September 28, 2013 and December 29, 2012 was estimated at $407.8 million and $533.3 million, respectively. Factors that we considered when estimating the fair value of our debt include market conditions, prepayment and make-whole provisions, liquidity levels in the private placement market, variability in pricing from multiple lenders and term of debt.
	Derivative contracts
	Derivative contracts are valued using quoted market prices and significant other observable and unobservable inputs. We use derivative instruments to minimize our exposure to fluctuations in foreign currency exchange rates. Our derivative instruments primarily include foreign currency forward agreements related to intercompany loans and certain forecasted inventory purchase commitments with suppliers.
	The fair values for the majority of our foreign currency derivative contracts are obtained by comparing our contract rate to a published forward price of the underlying market rates, which is based on market rates for comparable transactions and are classified within Level 2 of the fair value hierarchy.
	Redeemable noncontrolling interests
	Some minority shareholders in certain of our subsidiaries have the right, at certain times, to require us to acquire their ownership interest in those entities at fair value based on third-party valuations. The future value of redeemable noncontrolling interests is subject to expected earnings and, if such earnings are not achieved, the value of the redeemable noncontrolling interests might be impacted. The noncontrolling interests subject to put options are adjusted to their estimated redemption amounts each reporting period with a corresponding adjustment to Additional paid-in capital. Future reductions in the carrying amounts are subject to a “floor” amount that is equal to the fair value of the redeemable noncontrolling interests at the time they were originally recorded. The recorded value of the redeemable noncontrolling interests cannot go below the floor level. These adjustments do not impact the calculation of earnings per share. The values for Redeemable noncontrolling interests are classified within Level 3 of the fair value hierarchy. The details of the changes in Redeemable noncontrolling interests are presented in Note 4.
	The following table presents our assets and liabilities that are measured and recognized at fair value on a recurring basis classified under the appropriate level of the fair value hierarchy as of September 28, 2013 and December 29, 2012:
				28-Sep-13
					Level 1		Level 2		Level 3		Total
	Assets:
		Derivative contracts		$	-	$	474	$	-	$	474
			Total assets	$	-	$	474	$	-	$	474
	Liabilities:
		Derivative contracts		$	-	$	2,844	$	-	$	2,844
			Total liabilities	$	-	$	2,844	$	-	$	2,844
	Redeemable noncontrolling interests			$	-	$	-	$	475,021	$	475,021
				29-Dec-12
					Level 1		Level 2		Level 3		Total
	Assets:
		Available-for-sale securities		$	-	$	-	$	2,816	$	2,816
		Derivative contracts			-		710		-		710
			Total assets	$	-	$	710	$	2,816	$	3,526
	Liabilities:
		Derivative contracts		$	-	$	1,159	$	-	$	1,159
			Total liabilities	$	-	$	1,159	$	-	$	1,159
	Redeemable noncontrolling interests			$	-	$	-	$	435,175	$	435,175

Business_Acquisitions_and_Dive

Business Acquisitions and Divestiture	9 Months Ended
	Sep. 28, 2013
Business Combinations And Divestitures [Abstract]	'
Business Acquisitions and Divestiture	'
	Note 7 – Business Acquisitions and Divestiture of an Equity Affiliate
	Acquisitions
	The operating results of all acquisitions are reflected in our financial statements from their respective acquisition dates.
	We completed certain acquisitions during the nine months ended September 28, 2013. Such acquisitions were immaterial to our financial statements individually and in the aggregate.
	Some prior owners of such acquired subsidiaries are eligible to receive additional purchase price cash consideration if certain financial targets are met. For acquisitions completed prior to 2009, we accrue liabilities that may arise from these transactions when we believe that the outcome of the contingency is determinable beyond a reasonable doubt. For acquisitions completed in subsequent periods, we have accrued liabilities for the estimated fair value of additional purchase price consideration at the time of the acquisition. Any adjustments to these accrual amounts are recorded in our consolidated statements of income. For the nine months ended September 28, 2013 and September 29, 2012, there were no material adjustments recorded in our consolidated statement of income relating to changes in estimated contingent purchase price liabilities.
	Divestiture of an Equity Affiliate
	On July 10, 2013, we divested our investment in a dental wholesale distributor in the Middle East that had primarily served as an importer that distributed products largely to other distributors. The divestiture resulted in a one-time loss, which is recorded in a separate line item, “Loss on sale of equity investment” within our consolidated statements of income and within the cash flows from operating activities section of our consolidated statements of cash flows, of $12.5 million, or $0.14 per diluted share, in the third quarter of 2013. Pursuant to the terms of this divestiture, we made cash payments, which are recorded in a separate line item, “Payments related to sale of equity investment”, within the cash flows from investing activities section of our consolidated statements of cash flows, to this distributor in the aggregate amount of $13.4 million, which it was required to use to reduce its debt, pay certain trade payables and provide working capital.  The investment in this distributor had been fully impaired as of the end of 2012.  There is no tax benefit related to the loss on this divestiture.

Plans_of_Restructuring

Plans of Restructuring	9 Months Ended
	Sep. 28, 2013
Restructuring and Related Activities [Abstract]	'
Plans of Restructuring	'
	Note 8 – Plans of Restructuring
	During the year ended December 29, 2012, we incurred restructuring costs of $15.2 million ($10.5 million after taxes). These costs consisted of employee severance pay and benefits related to the elimination of approximately 200 positions; facility closing costs, representing primarily lease terminations and property and equipment write-off costs; and outside professional and consulting fees directly related to the restructuring plan. This restructuring program is complete and we do not expect any additional costs from this program.
	The costs associated with this restructuring are included in a separate line item, “Restructuring costs” within our consolidated statements of income.
	The following table shows the amounts expensed and paid for restructuring costs that were incurred during the nine months ended September 28, 2013 and during our 2012 fiscal year and the remaining accrued balance of restructuring costs as of September 28, 2013, which is included in Accrued expenses: Other and Other liabilities within our consolidated balance sheet:
				Facility
		Severance		Closing
		Costs		Costs		Total
	Balance, December 31, 2011	$	569	$	551	$	1,120
	Provision		12,841		2,351		15,192
	Payments and other adjustments		-11,584		-1,671		-13,255
	Balance, December 29, 2012	$	1,826	$	1,231	$	3,057
	Provision		-		-		-
	Payments and other adjustments		-1,261		-673		-1,934
	Balance, September 28, 2013	$	565	$	558	$	1,123
	The following table shows, by reportable segment, the restructuring costs incurred during the nine months ended September 28, 2013 and the 2012 fiscal year and the remaining accrued balance of restructuring costs as of September 28, 2013:
				Technology and
		Health Care		Value-Added
		Distribution		Services		Total
	Balance, December 31, 2011	$	1,120	$	-	$	1,120
	Provision		14,981		211		15,192
	Payments and other adjustments		-13,058		-197		-13,255
	Balance, December 29, 2012	$	3,043	$	14	$	3,057
	Provision		-		-		-
	Payments and other adjustments		-1,920		-14		-1,934
	Balance, September 28, 2013	$	1,123	$	-	$	1,123

Earnings_Per_Share

Earnings Per Share	9 Months Ended
	Sep. 28, 2013
Earnings Per Share [Abstract]	'
Earnings Per Share	'
	Note 9 – Earnings Per Share
	Basic earnings per share is computed by dividing net income attributable to Henry Schein, Inc. by the weighted-average number of common shares outstanding for the period. Our diluted earnings per share is computed similarly to basic earnings per share, except that it reflects the effect of common shares issuable for presently unvested restricted stock and restricted stock units and upon exercise of stock options, using the treasury stock method in periods in which they have a dilutive effect.
	A reconciliation of shares used in calculating earnings per basic and diluted share follows:
			Three Months Ended		Nine Months Ended
			September 28,	September 29,	September 28,	September 29,
			2013	2012	2013	2012
	Basic		85,646	87,465	86,208	87,802
	Effect of dilutive securities:
		Stock options, restricted stock and restricted stock units	1,758	2,182	1,759	2,273
		Diluted	87,404	89,647	87,967	90,075

Income_Taxes

Income Taxes	9 Months Ended
	Sep. 28, 2013
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	Note 10 – Income Taxes
	For the nine months ended September 28, 2013, our effective tax rate was 28.3% compared to 31.3% for the prior year period. During the third quarter of 2013, we concluded that it is more likely than not that certain deferred tax assets related to tax loss carryforwards originating outside the United States, which had been previously reserved, will be realized. As a result, our provision for income taxes includes a $13.4 million reduction of the valuation allowance which is based on an estimate of future taxable income available to be offset by the tax loss carryforwards.
	Absent the effects of the reduction of this valuation allowance in the third quarter of 2013, our effective tax rate for the nine months ended September 28, 2013 would have been 31.1% as compared to our actual effective tax rate of 28.3%. The remaining difference between our effective tax rates and the federal statutory tax rates for both periods primarily relates to state and foreign income taxes and interest expense.
	The total amount of unrecognized tax benefits as of September 28, 2013 was approximately $49.6 million, all of which would affect the effective tax rate if recognized.  It is expected that the amount of unrecognized tax benefits will change in the next 12 months; however, we do not expect the change to have a material impact on our consolidated financial statements.
	The total amounts of interest and penalties, which are classified as a component of the provision for income taxes, were approximately $9.8 million and $0, respectively, for the nine months ended September 28, 2013.
	The tax years subject to examination by major tax jurisdictions include the years 2009 and forward by the U.S. Internal Revenue Service, the years 1997 and forward for certain states and the years 2005 and forward for certain foreign jurisdictions.

Derivatives_and_Hedging_Activi

Derivatives and Hedging Activities	9 Months Ended
	Sep. 28, 2013
Derivative Instruments and Hedging Activities Disclosure [Abstract]	'
Derivatives and Hedging Activities	'
	Note 11 – Derivatives and Hedging Activities
	We are exposed to market risks as well as changes in foreign currency exchange rates as measured against the U.S. dollar and each other, and changes to the credit markets. We attempt to minimize these risks by primarily using foreign currency forward contracts and by maintaining counter-party credit limits. These hedging activities provide only limited protection against currency exchange and credit risks. Factors that could influence the effectiveness of our hedging programs include currency markets and availability of hedging instruments and liquidity of the credit markets. All foreign currency forward contracts that we enter into are components of hedging programs and are entered into for the sole purpose of hedging an existing or anticipated currency exposure. We do not enter into such contracts for speculative purposes and we manage our credit risks by diversifying our investments, maintaining a strong balance sheet and having multiple sources of capital.
	Fluctuations in the value of certain foreign currencies as compared to the U.S. dollar may positively or negatively affect our revenues, gross margins, operating expenses and retained earnings, all of which are expressed in U.S. dollars. Where we deem it prudent, we engage in hedging programs using primarily foreign currency forward contracts aimed at limiting the impact of foreign currency exchange rate fluctuations on earnings. We purchase short-term (i.e., 18 months or less) foreign currency forward contracts to protect against currency exchange risks associated with intercompany loans due from our international subsidiaries and the payment of merchandise purchases to our foreign suppliers. We do not hedge the translation of foreign currency profits into U.S. dollars, as we regard this as an accounting exposure, not an economic exposure. Our hedging activities have historically not had a material impact on our consolidated financial statements. Accordingly, additional disclosures related to derivatives and hedging activities required by ASC Topic 815 have been omitted.

StockBased_Compensation

Stock-Based Compensation	9 Months Ended
	Sep. 28, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Stock-Based Compensation	'
	Note 12 – Stock-Based Compensation
	Our accompanying unaudited consolidated statements of income reflect share-based pre-tax compensation expense of $8.0 million ($5.6 million after-tax) and $24.7 million ($17.0 million after-tax) for the three and nine months ended September 28, 2013, respectively, and $11.9 million ($8.2 million after-tax) and $31.9 million ($21.9 million after-tax) for the three and nine months ended September 29, 2012, respectively.
	Stock-based compensation represents the cost related to stock-based awards granted to employees and non-employee directors. We measure stock-based compensation at the grant date, based on the estimated fair value of the award, and recognize the cost (net of estimated forfeitures) as compensation expense on a straight-line basis over the requisite service period. Our stock-based compensation expense is reflected in selling, general and administrative expenses in our consolidated statements of income.
	Stock-based awards are provided to certain employees and non-employee directors under the terms of our 2013 Stock Incentive Plan, as amended, and our 1996 Non-Employee Director Stock Incentive Plan, as amended (together, the “Plans”). The Plans are administered by the Compensation Committee of the Board of Directors. Prior to March 2009, awards under the Plans principally included a combination of at-the-money stock options and restricted stock (including restricted stock units). Since March 2009, equity-based awards have been granted solely in the form of restricted stock and restricted stock units, with the exception of stock options for certain pre-existing contractual obligations.
	Grants of restricted stock are common stock awards granted to recipients with specified vesting provisions. We issue restricted stock that vests solely based on the recipient's continued service over time (primarily four-year cliff vesting) and restricted stock that vests based on our achieving specified performance measurements and the recipient's continued service over time (primarily three-year cliff vesting).
	With respect to time-based restricted stock, we estimate the fair value on the date of grant based on our closing stock price. With respect to performance-based restricted stock, the number of shares that ultimately vest and are received by the recipient is based upon our performance as measured against specified targets over a three-year period as determined by the Compensation Committee of the Board of Directors. Although there is no guarantee that performance targets will be achieved, we estimate the fair value of performance-based restricted stock based on our closing stock price at time of grant.
	The Plans provide for adjustments to the performance-based restricted stock targets for significant events such as acquisitions, divestitures, new business ventures and share repurchases. Over the performance period, the number of shares of common stock that will ultimately vest and be issued and the related compensation expense is adjusted upward or downward based upon our estimation of achieving such performance targets. The ultimate number of shares delivered to recipients and the related compensation cost recognized as an expense will be based on our actual performance metrics as defined under the Plans.
	Restricted stock units are awards that we grant to certain employees that entitle the recipient to shares of common stock upon vesting. We grant restricted stock units with the same time-based and performance-based vesting that we use for restricted stock. The fair value of restricted stock units is determined on the date of grant, based on our closing stock price.
	Total unrecognized compensation cost related to non-vested awards as of September 28, 2013 was $82.1 million, which is expected to be recognized over a weighted-average period of approximately 2.2 years.
	The following table summarizes stock option activity under the Plans during the nine months ended September 28, 2013:
					Weighted
					Average
			Weighted		Remaining
			Average		Contractual		Aggregate
			Exercise		Life in		Intrinsic
		Shares	Price		Years		Value
	Outstanding at beginning of period	2,138	$	48.61
	Granted	-		-
	Exercised	-544		41.91
	Forfeited	-		-
	Outstanding at end of period	1,594	$	50.89	3.2		$	83,814
	Options exercisable at end of period	1,594	$	50.89	3.2		$	83,814
	The following tables summarize the activity of our non-vested restricted stock/units for the nine months ended September 28, 2013:
		Time-Based Restricted Stock/Units
			Weighted Average
			Grant Date Fair			Intrinsic Value
		Shares/Units	Value Per Share			Per Share
	Outstanding at beginning of period	1,018	$	56.87
	Granted	210		89.22
	Vested	-280		35.59
	Forfeited	-24		69.29
	Outstanding at end of period	924	$	70.35		$	103.48
		Performance-Based Restricted Stock/Units
			Weighted Average
			Grant Date Fair			Intrinsic Value
		Shares/Units	Value Per Share			Per Share
	Outstanding at beginning of period	1,315	$	53.27
	Granted	167		82.83
	Vested	-363		56.55
	Forfeited	-20		74.24
	Outstanding at end of period	1,099	$	60.44		$	103.48

Supplemental_Cash_Flow_Informa

Supplemental Cash Flow Information	9 Months Ended
	Sep. 28, 2013
Supplemental Cash Flow Elements [Abstract]	'
Supplemental Cash Flow Information	'
	Note 13 – Supplemental Cash Flow Information
	Cash paid for interest and income taxes was:
		Nine Months Ended
		September 28,		September 29,
		2013		2012
	Interest	$	16,969	$	18,756
	Income taxes		82,869		139,430
	During the nine months ended September 28, 2013, we had a $0.7 million non-cash net unrealized loss related to hedging activities. During the nine months ended September 29, 2012, we had a $0.5 million non-cash net unrealized gain related to hedging activities.

Segment_Data_Tables

Segment Data (Tables)	9 Months Ended
	Sep. 28, 2013
Segment Reporting [Abstract]	'
Business segment information	'
					Three Months Ended				Nine Months Ended
					September 28,		September 29,		September 28,		September 29,
					2013		2012		2013		2012
	Net Sales:
		Health care distribution (1):
			Dental		$	1,183,201	$	1,119,430	$	3,633,577	$	3,461,015
			Animal health			642,289		598,124		1,947,728		1,709,972
			Medical			444,533		442,538		1,221,282		1,158,486
				Total health care distribution		2,270,023		2,160,092		6,802,587		6,329,473
		Technology and value-added services (2)				78,933		70,966		231,690		202,056
			Total		$	2,348,956	$	2,231,058	$	7,034,277	$	6,531,529
	-1	Consists of consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and
		generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.
	-2	Consists of practice management software and other value-added products, which are distributed primarily to health care providers, and
		financial and other services, including e-services and continuing education services for practitioners.
					Three Months Ended				Nine Months Ended
					September 28,		September 29,		September 28,		September 29,
					2013		2012		2013		2012
	Operating Income:
		Health care distribution			$	139,949	$	129,932	$	429,091	$	383,200
		Technology and value-added services				20,528		19,690		61,080		54,419
			Total		$	160,477	$	149,622	$	490,171	$	437,619

Debt_Tables

Debt (Tables)	9 Months Ended
	Sep. 28, 2013
Debt Disclosure [Abstract]	'
Private Placement Facilities	'
		Amount of
		Borrowing		Borrowing
	Date of Borrowing	Outstanding		Rate		Due Date
	2-Sep-10	$	100,000	3.79	%	2-Sep-20
	20-Jan-12		50,000	3.45		20-Jan-24
	January 20, 2012 (1)		50,000	3.09		20-Jan-22
	24-Dec-12		50,000	3		24-Dec-24
		$	250,000
	(1) Annual repayments of approximately $7.1 million for this borrowing will commence on January 20, 2016.

Redeemable_Noncontrolling_Inte1

Redeemable Noncontrolling Interests (Tables)	9 Months Ended
	Sep. 28, 2013
Temporary Equity Disclosure [Abstract]	'
Change in fair value of redeemable noncontrolling interests	'
			September 28,		December 29,
			2013		2012
	Balance, beginning of period		$	435,175	$	402,050
	Decrease in redeemable noncontrolling interests due to
		redemptions		-5,124		-23,637
	Increase in redeemable noncontrolling interests due to business
		acquisitions		9,676		30,935
	Net income attributable to redeemable noncontrolling interests			28,872		34,803
	Dividends declared			-17,714		-21,013
	Effect of foreign currency translation gain (loss) attributable to
		redeemable noncontrolling interests		-319		904
	Change in fair value of redeemable securities			24,455		53,769
	Other adjustment to redeemable noncontrolling interests			-		-42,636
	Balance, end of period		$	475,021	$	435,175

Comprehensive_Income_Tables

Comprehensive Income (Tables)	9 Months Ended
	Sep. 28, 2013
Comprehensive Income [Abstract]	'
Accumulated other comprehensive income, net of applicable taxes	'
					September 28,			December 29,
					2013			2012
	Attributable to Redeemable noncontrolling interests:
			Foreign currency translation adjustment		$	-1,168		$	-849
	Attributable to Henry Schein, Inc.:
		Foreign currency translation gain			$	70,597		$	72,160
		Unrealized gain from foreign currency hedging activities				649			1,187
		Unrealized investment loss				-508			-415
		Pension adjustment loss				-19,587			-20,077
			Accumulated other comprehensive income		$	51,151		$	52,855
	Total Accumulated other comprehensive income				$	49,983		$	52,006
Components of comprehensive income, net of applicable taxes	'
			Three Months Ended						Nine Months Ended
			September 28,			September 29,			September 28,			September 29,
			2013			2012			2013			2012
	Net income		$	116,372		$	105,310		$	336,493		$	301,673
	Foreign currency translation gain (loss)			53,820			22,606			-1,882			12,263
	Tax effect			-			-			-			-
	Foreign currency translation gain (loss)			53,820			22,606			-1,882			12,263
	Unrealized gain (loss) from foreign currency hedging
	activities			-1,550			608			-694			518
	Tax effect			378			-88			156			-105
	Unrealized gain (loss) from foreign currency hedging
	activities			-1,172			520			-538			413
	Unrealized investment gain (loss)			-17			197			-155			380
	Tax effect			7			-77			62			-172
	Unrealized investment gain (loss)			-10			120			-93			208
	Pension adjustment gain (loss)			-696			-91			567			241
	Tax effect			179			83			-77			-203
	Pension adjustment gain (loss)			-517			-8			490			38
	Comprehensive income		$	168,493		$	128,548		$	334,470		$	314,595
Total comprehensive income, net of applicable taxes	'
				Three Months Ended						Nine Months Ended
				September 28,			September 29,			September 28,			September 29,
				2013			2012			2013			2012
	Comprehensive income attributable to
		Henry Schein, Inc.		$	157,264		$	119,366		$	305,582		$	288,500
	Comprehensive income attributable to
		noncontrolling interests			146			109			335			323
	Comprehensive income attributable to
		Redeemable noncontrolling interests			11,083			9,073			28,553			25,772
	Comprehensive income			$	168,493		$	128,548		$	334,470		$	314,595

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 28, 2013
Fair Value Disclosures [Abstract]	'
Fair value - assets and liabilities measured and recognized on a recurring basis	'
				28-Sep-13
					Level 1		Level 2		Level 3		Total
	Assets:
		Derivative contracts		$	-	$	474	$	-	$	474
			Total assets	$	-	$	474	$	-	$	474
	Liabilities:
		Derivative contracts		$	-	$	2,844	$	-	$	2,844
			Total liabilities	$	-	$	2,844	$	-	$	2,844
	Redeemable noncontrolling interests			$	-	$	-	$	475,021	$	475,021
				29-Dec-12
					Level 1		Level 2		Level 3		Total
	Assets:
		Available-for-sale securities		$	-	$	-	$	2,816	$	2,816
		Derivative contracts			-		710		-		710
			Total assets	$	-	$	710	$	2,816	$	3,526
	Liabilities:
		Derivative contracts		$	-	$	1,159	$	-	$	1,159
			Total liabilities	$	-	$	1,159	$	-	$	1,159
	Redeemable noncontrolling interests			$	-	$	-	$	435,175	$	435,175

Plans_of_Restructuring_Tables

Plans of Restructuring (Tables)	9 Months Ended
	Sep. 28, 2013
Restructuring and Related Activities [Abstract]	'
Schedule of restructuring reserve by type of cost	'
				Facility
		Severance		Closing
		Costs		Costs		Total
	Balance, December 31, 2011	$	569	$	551	$	1,120
	Provision		12,841		2,351		15,192
	Payments and other adjustments		-11,584		-1,671		-13,255
	Balance, December 29, 2012	$	1,826	$	1,231	$	3,057
	Provision		-		-		-
	Payments and other adjustments		-1,261		-673		-1,934
	Balance, September 28, 2013	$	565	$	558	$	1,123
Schedule of restructuring reserve by segment	'
				Technology and
		Health Care		Value-Added
		Distribution		Services		Total
	Balance, December 31, 2011	$	1,120	$	-	$	1,120
	Provision		14,981		211		15,192
	Payments and other adjustments		-13,058		-197		-13,255
	Balance, December 29, 2012	$	3,043	$	14	$	3,057
	Provision		-		-		-
	Payments and other adjustments		-1,920		-14		-1,934
	Balance, September 28, 2013	$	1,123	$	-	$	1,123

Earnings_Per_Share_Tables

Earnings Per Share (Tables)	9 Months Ended
	Sep. 28, 2013
Earnings Per Share [Abstract]	'
Reconciliation of basic and diluted shares used to calculate earnings per share	'
			Three Months Ended		Nine Months Ended
			September 28,	September 29,	September 28,	September 29,
			2013	2012	2013	2012
	Basic		85,646	87,465	86,208	87,802
	Effect of dilutive securities:
		Stock options, restricted stock and restricted stock units	1,758	2,182	1,759	2,273
		Diluted	87,404	89,647	87,967	90,075

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 28, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Summary of the stock option activity under the plans	'
					Weighted
					Average
			Weighted		Remaining
			Average		Contractual		Aggregate
			Exercise		Life in		Intrinsic
		Shares	Price		Years		Value
	Outstanding at beginning of period	2,138	$	48.61
	Granted	-		-
	Exercised	-544		41.91
	Forfeited	-		-
	Outstanding at end of period	1,594	$	50.89	3.2		$	83,814
	Options exercisable at end of period	1,594	$	50.89	3.2		$	83,814
Status of non-vested restricted shares/units	'
		Time-Based Restricted Stock/Units
			Weighted Average
			Grant Date Fair			Intrinsic Value
		Shares/Units	Value Per Share			Per Share
	Outstanding at beginning of period	1,018	$	56.87
	Granted	210		89.22
	Vested	-280		35.59
	Forfeited	-24		69.29
	Outstanding at end of period	924	$	70.35		$	103.48
		Performance-Based Restricted Stock/Units
			Weighted Average
			Grant Date Fair			Intrinsic Value
		Shares/Units	Value Per Share			Per Share
	Outstanding at beginning of period	1,315	$	53.27
	Granted	167		82.83
	Vested	-363		56.55
	Forfeited	-20		74.24
	Outstanding at end of period	1,099	$	60.44		$	103.48

Supplemental_Cash_Flow_Informa1

Supplemental Cash Flow Information (Tables)	9 Months Ended
	Sep. 28, 2013
Supplemental Cash Flow Elements [Abstract]	'
Cash paid for interest and income taxes	'
		Nine Months Ended
		September 28,		September 29,
		2013		2012
	Interest	$	16,969	$	18,756
	Income taxes		82,869		139,430

Segment_Data_Details

Segment Data (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 28, 2013	Sep. 29, 2012	Sep. 28, 2013	Sep. 29, 2012
	number		number
Segment Reporting [Abstract]	'	'	'	'
Number of reportable segments	'	'	2	'
Number of countries served globally	25	'	25	'
Segment Reporting Information [Line Items]	'	'	'	'
Net sales	$2,348,956	$2,231,058	$7,034,277	$6,531,529
Operating income	160,477	149,622	490,171	437,619
Health Care Distribution [Member]	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Net sales	2,270,023	2,160,092	6,802,587	6,329,473
Operating income	139,949	129,932	429,091	383,200
Health Care Distribution [Member] | Dental [Member]	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Net sales	1,183,201	1,119,430	3,633,577	3,461,015
Health Care Distribution [Member] | Medical [Member]	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Net sales	444,533	442,538	1,221,282	1,158,486
Health Care Distribution [Member] | Animal Health [Member]	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Net sales	642,289	598,124	1,947,728	1,709,972
Technology and Value-Added Services [Member]	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Net sales	78,933	70,966	231,690	202,056
Operating income	$20,528	$19,690	$61,080	$54,419

Debt_Details

Debt (Details) (USD $)	9 Months Ended
	Sep. 28, 2013	Sep. 29, 2012
Line of Credit Facility [Line Items]	'	'
Weighted average interest rate on borrowings under credit lines at period end (in hundredths)	4.26%	'
Debt Instrument [Line Items]	'	'
Accelerated amortization of deferred financing costs	$6,203,000	$0
Private placement facilities [Member]	'	'
Debt Instrument [Line Items]	'	'
Minimum term of issuances under private placement facilities (in years)	'five	'
Maximum term of issuances under private placement facilities (in years)	'15	'
Maximum average life of issuances under private placement facilities (in years)	'12	'
Issuance period (in years)	'three	'
Debt instrument carrying amount	250,000,000	'
Private placement facilities original borrowing [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt instrument, face amount	400,000,000	'
Number of insurance companies providing private placement facilities (in number of insurance companies)	'two	'
Private placement facilities additional borrowing [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt instrument, face amount	375,000,000	'
Number of insurance companies providing private placement facilities (in number of insurance companies)	'one	'
Private placement facilities maturing in September 2020 [Member]	'	'
Debt Instrument [Line Items]	'	'
Date of borrowing	2-Sep-10	'
Due date	2-Sep-20	'
Debt instrument carrying amount	100,000,000	'
Debt instrument, interest rate, stated percentage (in hundredths)	3.79%	'
Private placement facilities maturing in January 2024 [Member]	'	'
Debt Instrument [Line Items]	'	'
Date of borrowing	20-Jan-12	'
Due date	20-Jan-24	'
Debt instrument carrying amount	50,000,000	'
Debt instrument, interest rate, stated percentage (in hundredths)	3.45%	'
Private placement facilities maturing in January 2022 [Member]	'	'
Debt Instrument [Line Items]	'	'
Date of borrowing	20-Jan-12	'
Due date	20-Jan-22	'
Private placement facility annual payment	7,100,000	'
Private placement facility annual payment commencement date	20-Jan-16	'
Debt instrument carrying amount	50,000,000	'
Debt instrument, interest rate, stated percentage (in hundredths)	3.09%	'
Private placement facilities maturing in December 2024 [Member]	'	'
Debt Instrument [Line Items]	'	'
Date of borrowing	24-Dec-12	'
Due date	24-Dec-24	'
Debt instrument carrying amount	50,000,000	'
Debt instrument, interest rate, stated percentage (in hundredths)	3.00%	'
Henry Schein Animal Health debt [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt instrument carrying amount	220,000,000	'
Accelerated amortization of deferred financing costs	6,200,000	'
U.S. trade accounts receivable securitization [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt instrument, face amount	300,000,000	'
Debt instrument carrying amount	20,000,000	'
Pricing commitment period	'three	'
Debt instrument, basis spread on variable rate	0.75%	'
Commitment fee for facility usage - facility limit greater than or equal to fifty percent usage (in basis points)	30	'
Commitment fee for facility usage - facility limit less than fifty percent usage (in basis points)	35	'
Current revolving credit facility [Member]	'	'
Line of Credit Facility [Line Items]	'	'
Revolving credit facility borrowing capacity	500,000,000	'
Additional credit available under expansion feature of revolving credit facility	200,000,000	'
Revolving credit facility expiration date	12-Sep-17	'
Outstanding letters of credit provided to third parties	10,100,000	'
Line of credit facility, amount outstanding	0	'
Previous revolving credit facility [Member]	'	'
Line of Credit Facility [Line Items]	'	'
Revolving credit facility borrowing capacity	400,000,000	'
Additional credit available under expansion feature of revolving credit facility	100,000,000	'
Revolving credit facility expiration date	5-Sep-13	'
Various other short-term bank credit lines [Member]	'	'
Line of Credit Facility [Line Items]	'	'
Line of credit facility, amount outstanding	$15,800,000	'

Debt_Shortterm_Details

Debt - Short-term (Details) (Term loan note [Member], USD $)	9 Months Ended
In Millions, unless otherwise specified	Sep. 28, 2013
Term loan note [Member]	'
Short-term Debt [Line Items]	'
Debt instrument total amount	$100
Debt instrument carrying amount	$75
Debt instrument, basis spread on variable rate	0.75%

Redeemable_Noncontrolling_Inte2

Redeemable Noncontrolling Interests (Details) (USD $)	9 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Sep. 28, 2013	Dec. 29, 2012
Components of the change in the redeemable noncontrolling interests [Abstract]	'	'
Balance, beginning of period	$435,175	$402,050
Decrease in redeemable noncontrolling interests due to redemptions	-5,124	-23,637
Increase in redeemable noncontrolling interests due to business acquisitions	9,676	30,935
Net income attributable to redeemable noncontrolling interests	28,872	34,803
Dividends declared	-17,714	-21,013
Foreign currency translation gain (loss) attributable to redeemable noncontrolling interests	-319	904
Change in fair value of redeemable securities	24,455	53,769
Other adjustment to redeemable noncontrolling interests	0	-42,636
Balance, end of period	$475,021	$435,175

Comprehensive_Income_Accumulat

Comprehensive Income - Accumulated Other Comprehensive Income and Comprehensive Income Components (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 28, 2013	Sep. 29, 2012	Sep. 28, 2013	Sep. 29, 2012	Dec. 29, 2012
Attributable to Redeemable noncontrolling interests:	'	'	'	'	'
Foreign currency translation adjustment	($1,168)	'	($1,168)	'	($849)
Attributable to Henry Schein, Inc.:	'	'	'	'	'
Foreign currency translation gain (loss)	70,597	'	70,597	'	72,160
Unrealized gain (loss) from foreign currency hedging activities	649	'	649	'	1,187
Unrealized investment gain (loss)	-508	'	-508	'	-415
Pension adjustment gain (loss)	-19,587	'	-19,587	'	-20,077
Accumulated other comprehensive income (loss)	51,151	'	51,151	'	52,855
Total Accumulated other comprehensive income (loss)	49,983	'	49,983	'	52,006
Components of comprehensive income [Abstract]	'	'	'	'	'
Net income	116,372	105,310	336,493	301,673	'
Foreign currency translation gain (loss)	53,820	22,606	-1,882	12,263	'
Tax effect	0	0	0	0	'
Foreign currency translation gain (loss)	53,820	22,606	-1,882	12,263	'
Unrealized gain (loss) from foreign currency hedging activities	-1,550	608	-694	518	'
Tax effect	378	-88	156	-105	'
Unrealized gain (loss) from foreign currency hedging activities	-1,172	520	-538	413	'
Unrealized investment gain (loss)	-17	197	-155	380	'
Tax effect	7	-77	62	-172	'
Unrealized investment gain (loss)	-10	120	-93	208	'
Pension adjustment gain (loss)	-696	-91	567	241	'
Tax effect	179	83	-77	-203	'
Pension adjustment gain (loss)	-517	-8	490	38	'
Comprehensive income	$168,493	$128,548	$334,470	$314,595	'

Comprehensive_Income_Total_Com

Comprehensive Income - Total Comprehensive Income (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 28, 2013	Sep. 29, 2012	Sep. 28, 2013	Sep. 29, 2012
Comprehensive Income Net Of Applicable Taxes [Abstract]	'	'	'	'
Comprehensive income attributable to Henry Schein, Inc.	$157,264	$119,366	$305,582	$288,500
Comprehensive income attributable to noncontrolling interests	146	109	335	323
Comprehensive income attributable to Redeemable noncontrolling interests	11,083	9,073	28,553	25,772
Comprehensive income	$168,493	$128,548	$334,470	$314,595

Fair_Value_Measurements_Detail

Fair Value Measurements (Details) (USD $)	9 Months Ended
	Sep. 28, 2013	Dec. 29, 2012	Dec. 31, 2011
	number
Fair Value Disclosures [Abstract]	'	'	'
Number of levels in fair value hierarchy	3	'	'
Fair value of debt	$407,800,000	$533,300,000	'
Assets: [Abstracts]	'	'	'
Available-for-sale securities	'	2,816,000	'
Derivative contracts - assets	474,000	710,000	'
Total assets	474,000	3,526,000	'
Liabilities: [Abstracts]	'	'	'
Derivative contracts - liabilities	2,844,000	1,159,000	'
Total liabilities	2,844,000	1,159,000	'
Redeemable Noncontrolling Interests [Abstract]	'	'	'
Redeemable noncontrolling interests	475,021,000	435,175,000	402,050,000
Level 1 [Member]	'	'	'
Assets: [Abstracts]	'	'	'
Available-for-sale securities	'	0	'
Derivative contracts - assets	0	0	'
Total assets	0	0	'
Liabilities: [Abstracts]	'	'	'
Derivative contracts - liabilities	0	0	'
Total liabilities	0	0	'
Redeemable Noncontrolling Interests [Abstract]	'	'	'
Redeemable noncontrolling interests	0	0	'
Level 2 [Member]	'	'	'
Assets: [Abstracts]	'	'	'
Available-for-sale securities	'	0	'
Derivative contracts - assets	474,000	710,000	'
Total assets	474,000	710,000	'
Liabilities: [Abstracts]	'	'	'
Derivative contracts - liabilities	2,844,000	1,159,000	'
Total liabilities	2,844,000	1,159,000	'
Redeemable Noncontrolling Interests [Abstract]	'	'	'
Redeemable noncontrolling interests	0	0	'
Level 3 [Member]	'	'	'
Assets: [Abstracts]	'	'	'
Available-for-sale securities	'	2,816,000	'
Derivative contracts - assets	0	0	'
Total assets	0	2,816,000	'
Liabilities: [Abstracts]	'	'	'
Derivative contracts - liabilities	0	0	'
Total liabilities	0	0	'
Redeemable Noncontrolling Interests [Abstract]	'	'	'
Redeemable noncontrolling interests	$475,021,000	$435,175,000	'

Business_Acquisitions_and_Dive1

Business Acquisitions and Divestiture (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 28, 2013	Sep. 29, 2012	Sep. 28, 2013	Sep. 29, 2012
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]	'	'	'	'
Loss on sale of equity investment	($12,535)	$0	($12,535)	$0
Payments related to sale of equity investment	'	'	13,364	0
Middle East equity affiliate [Member]	'	'	'	'
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]	'	'	'	'
Loss on sale of equity investment	'	'	12,500	'
Loss on sale of equity investment per diluted share	'	'	$0.14	'
Payments related to sale of equity investment	'	'	$13,400	'

Plans_of_Restructuring_Details

Plans of Restructuring (Details) (USD $)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 28, 2013	Sep. 29, 2012	Sep. 28, 2013	Sep. 29, 2012	Dec. 29, 2012
					number
Restructuring and Related Activities [Abstract]	'	'	'	'	'
Positions eliminated from operations (in positions)	'	'	'	'	200
Restructuring costs	$0	$0	$0	$15,192,000	$15,192,000
Restructuring costs after-tax	'	'	'	'	10,500,000
Restructuring Reserve [Roll Forward]	'	'	'	'	'
Restructuring Reserve, beginning balance	'	'	3,057,000	1,120,000	1,120,000
Provision	0	0	0	15,192,000	15,192,000
Payments and other adjustments	'	'	-1,934,000	'	-13,255,000
Restructuring Reserve, ending balance	1,123,000	'	1,123,000	'	3,057,000
Health Care Distribution [Member]	'	'	'	'	'
Restructuring and Related Activities [Abstract]	'	'	'	'	'
Restructuring costs	'	'	0	'	14,981,000
Restructuring Reserve [Roll Forward]	'	'	'	'	'
Restructuring Reserve, beginning balance	'	'	3,043,000	1,120,000	1,120,000
Provision	'	'	0	'	14,981,000
Payments and other adjustments	'	'	-1,920,000	'	-13,058,000
Restructuring Reserve, ending balance	1,123,000	'	1,123,000	'	3,043,000
Technology and Value-Added Services [Member]	'	'	'	'	'
Restructuring and Related Activities [Abstract]	'	'	'	'	'
Restructuring costs	'	'	0	'	211,000
Restructuring Reserve [Roll Forward]	'	'	'	'	'
Restructuring Reserve, beginning balance	'	'	14,000	0	0
Provision	'	'	0	'	211,000
Payments and other adjustments	'	'	-14,000	'	-197,000
Restructuring Reserve, ending balance	0	'	0	'	14,000
Severance costs [Member]	'	'	'	'	'
Restructuring and Related Activities [Abstract]	'	'	'	'	'
Restructuring costs	'	'	0	'	12,841,000
Restructuring Reserve [Roll Forward]	'	'	'	'	'
Restructuring Reserve, beginning balance	'	'	1,826,000	569,000	569,000
Provision	'	'	0	'	12,841,000
Payments and other adjustments	'	'	-1,261,000	'	-11,584,000
Restructuring Reserve, ending balance	565,000	'	565,000	'	1,826,000
Facility closing costs [Member]	'	'	'	'	'
Restructuring and Related Activities [Abstract]	'	'	'	'	'
Restructuring costs	'	'	0	'	2,351,000
Restructuring Reserve [Roll Forward]	'	'	'	'	'
Restructuring Reserve, beginning balance	'	'	1,231,000	551,000	551,000
Provision	'	'	0	'	2,351,000
Payments and other adjustments	'	'	-673,000	'	-1,671,000
Restructuring Reserve, ending balance	$558,000	'	$558,000	'	$1,231,000

Earnings_Per_Share_Details

Earnings Per Share (Details)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 28, 2013	Sep. 29, 2012	Sep. 28, 2013	Sep. 29, 2012
Weighted-average common shares outstanding:	'	'	'	'
Basic (in shares)	85,646	87,465	86,208	87,802
Effect of dilutive securities:	'	'	'	'
Stock options, restricted stock and restricted stock units (in shares)	1,758	2,182	1,759	2,273
Diluted (in shares)	87,404	89,647	87,967	90,075

Income_Taxes_Details

Income Taxes (Details) (USD $)	9 Months Ended
	Sep. 28, 2013	Sep. 29, 2012
Income Tax Disclosure [Abstract]	'	'
Effective tax rate (in hundredths)	28.30%	31.30%
Valuation allowance, deferred tax asset, change in amount	$13,400,000	'
Effective tax rate without effect of reduction in valuation allowance (in hundredths)	31.10%	'
Unrecognized tax benefits	49,600,000	'
Total interest	9,800,000	'
Total penalites	$0	'

StockBased_Compensation_Detail

Stock-Based Compensation (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 28, 2013	Sep. 29, 2012	Sep. 28, 2013	Sep. 29, 2012
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'	'	'	'
Pre-tax share-based compensation expense	$8,000,000	$11,900,000	$24,695,000	$31,867,000
After-tax share-based compensation expense	5,600,000	8,200,000	17,000,000	21,900,000
Total unrecognized compensation cost related to non-vested awards	82,100,000	'	82,100,000	'
Weighted-average period of recognition for unrecognized compensation costs on nonvested awards (in years)	'	'	'2 years 2 months 26 days	'
Stock options for common stock [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]	'	'	'	'
Outstanding at beginning of period (in shares)	'	'	2,138,000	'
Granted (in shares)	'	'	0	'
Exercised (in shares)	'	'	-544,000	'
Forfeited (in shares)	'	'	0	'
Outstanding at end of period (in shares)	1,594,000	'	1,594,000	'
Ending balance, options exercisable (in shares)	1,594,000	'	1,594,000	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]	'	'	'	'
Outstanding at beginning of period (in dollars per share)	'	'	$48.61	'
Granted (in dollars per share)	'	'	$0	'
Exercised (in dollars per share)	'	'	$41.91	'
Forfeited (in dollars per share)	'	'	$0	'
Outstanding at end of period (in dollars per share)	$50.89	'	$50.89	'
Ending balance, options exercisable (in dollars per share)	$50.89	'	$50.89	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]	'	'	'	'
Stock option oustanding aggregate intrinsic value as of period end	83,814,000	'	83,814,000	'
Stock option exercisable aggregate intrinsic value as of period end	$83,814,000	'	$83,814,000	'
Weighted average remaining contractual life, options outstanding (in years)	'	'	'3 years 1 month 28 days	'
Weighted average remaining contractual life, options exercisable (in years)	'	'	'3 years 1 month 28 days	'
Time-based restricted stock/units [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Number of years for full vesting (in years)	'	'	'4 years 0 months 0 days	'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested [Roll Forward]	'	'	'	'
Beginning balance outstanding (in shares)	'	'	1,018,000	'
Granted (in shares)	'	'	210,000	'
Vested (in shares)	'	'	-280,000	'
Forfeited (in shares)	'	'	-24,000	'
Ending balance outstanding (in shares)	924,000	'	924,000	'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Roll Forward]	'	'	'	'
Beginning balance outstanding (in dollars per share)	'	'	$56.87	'
Granted (in dollars per share)	'	'	$89.22	'
Vested (in dollars per share)	'	'	$35.59	'
Forfeited (in dollars per share)	'	'	$69.29	'
Ending balance outstanding (in dollars per share)	$70.35	'	$70.35	'
Intrinsic value (in dollars per share)	$103.48	'	$103.48	'
Performance-based restricted stock/units [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Number of years for full vesting (in years)	'	'	'3 years 0 months 0 days	'
Period over which earnings per share performance is measured against specified targets (in years)	'	'	'three	'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested [Roll Forward]	'	'	'	'
Beginning balance outstanding (in shares)	'	'	1,315,000	'
Granted (in shares)	'	'	167,000	'
Vested (in shares)	'	'	-363,000	'
Forfeited (in shares)	'	'	-20,000	'
Ending balance outstanding (in shares)	1,099,000	'	1,099,000	'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Roll Forward]	'	'	'	'
Beginning balance outstanding (in dollars per share)	'	'	$53.27	'
Granted (in dollars per share)	'	'	$82.83	'
Vested (in dollars per share)	'	'	$56.55	'
Forfeited (in dollars per share)	'	'	$74.24	'
Ending balance outstanding (in dollars per share)	$60.44	'	$60.44	'
Intrinsic value (in dollars per share)	$103.48	'	$103.48	'

Supplemental_Cash_Flow_Informa2

Supplemental Cash Flow Information (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 28, 2013	Sep. 29, 2012	Sep. 28, 2013	Sep. 29, 2012
Supplemental Cash Flow Information [Abstract]	'	'	'	'
Interest	'	'	$16,969	$18,756
Income taxes	'	'	82,869	139,430
Unrealized gain (loss) from foreign currency hedging activities	($1,550)	$608	($694)	$518